Results 121 to 130 of about 52,382 (294)

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

open access: yesCancer Science, EarlyView.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang   +16 more
wiley   +1 more source

Population‐Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole‐Genome Sequencing in Japan

open access: yesCancer Science, EarlyView.
Whole‐genome sequencing of ~50,000 individuals from the Tohoku Medical Megabank (TMM) cohort defines the prevalence, mutational landscape, and age dependency of clonal hematopoiesis in the Japanese population, demonstrating overall concordance with clonal hematopoiesis detected in cancer patients.
SungGi Chi   +12 more
wiley   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese   +12 more
wiley   +1 more source

Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment

open access: yesBiomedicines
Myelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis
Fabio Stagno   +6 more
doaj   +1 more source

Long‐Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Myelodysplastic neoplasia (MDS) comprises heterogeneous clonal hematologic disorders characterized by peripheral cytopenia, bone marrow dysplasia, and a risk of leukemic transformation. A hypoplastic variant (MDS‐h) shares features with aplastic anemia and responds to immunosuppressive therapy (IST).
Hannes Treiber   +8 more
wiley   +1 more source

Single‐cell transcriptional consequences of leukaemogenic SETBP1 mutations

open access: yes
British Journal of Haematology, EarlyView.
Mi K. Trinh   +15 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

Myelodysplastic syndrome [PDF]

open access: yesCanadian Medical Association Journal, 2016
Richard A, Wells   +2 more
openaire   +2 more sources

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo   +2 more
wiley   +1 more source

The wolf of hypomethylating agent failure: what comes next?

open access: yesHaematologica, 2019
Anne Sophie Kubasch, Uwe Platzbecker
doaj   +1 more source

Home - About - Disclaimer - Privacy